Current Report Filing (8-k)
18 January 2023 - 10:04PM
Edgar (US Regulatory)
0001860657
false
0001860657
2023-01-13
2023-01-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13, 2023
ALLARITY THERAPEUTICS, INC.
(Exact name of registrant as specified in our charter)
Delaware |
|
001-41160 |
|
87-2147982 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
24 School Street, 2nd Floor,
Boston, MA |
|
02108 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(401) 426-4664
(Registrant’s telephone number, including
area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
ALLR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
As of January 13, 2023, the
Company had 18,367,757 shares of common stock outstanding. Since December 2021, the Company has issued 10,291,933 shares of common stock
as a result of exercise of conversions of 6,965 shares of Series A Preferred Stock. As of January 13, 2023, there were 13,035 shares of
Series A Preferred Stock issued and outstanding.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Allarity Therapeutics, Inc. |
|
|
|
By: |
/s/ James G.
Cullem |
|
|
James G. Cullem
Chief Executive Officer |
|
|
|
Dated: January 17, 2023 |
|
|
2
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Apr 2023 to Apr 2024